UMN Pharma will use the PERC6 cell line in its UMN-03 project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type 2 diabetes mellitus.
In addition, Crucell and DSM Biologics will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing.
Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details were not disclosed.
Crucell NV is a biotechnology company focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases.